Amylin Analogues in Research: Cagrilintide and Eloralintide

Amylin analogues have become one of the most closely watched groups in metabolic research. Amylin is a peptide released by pancreatic beta cells together with insulin, and its receptors act in the central nervous system, the stomach and peripheral tissues. The native molecule is demanding to work with in the lab because it aggregates readily, so research teams design analogues that keep receptor activity while behaving predictably in solution. This guide covers cagrilintide, eloralintide, amylin receptors, and the reasons amylin is so often studied alongside GLP-1 agonists.

What amylin is

Amylin (IAPP) is a 37-residue peptide. Its structure includes a disulfide bridge between two cysteine residues and a C-terminal amide, and both features matter for biological activity. Physiologically, amylin is secreted with insulin in response to a meal. In research models, it has been linked to gastric emptying, glucagon secretion and satiety signalling in the central nervous system.

The native peptide tends to aggregate, which makes solutions difficult to handle. That is the main reason researchers turn to modified analogues with better stability.

Amylin receptors: AMY1, AMY2 and AMY3

Amylin receptors are not a single protein. They form when the calcitonin receptor (CTR) pairs with receptor activity-modifying proteins, known as RAMPs. The calcitonin receptor on its own responds mainly to calcitonin, while the presence of a RAMP shifts its ligand selectivity. Depending on which RAMP joins the complex, three variants arise.

Receptor	Components	Role in research
Calcitonin receptor	CTR without RAMP	reference point in selectivity assays
AMY1	CTR + RAMP1	separate target when comparing ligands
AMY2	CTR + RAMP2	model for studying receptor subtypes
AMY3	CTR + RAMP3	model for studying receptor subtypes

The practical takeaway for a lab is straightforward. Assays on cell lines with different RAMP expression let you separate activity at each subtype, and that changes how you read the results.

Cagrilintide: a long-acting amylin analogue

Cagrilintide is an amylin analogue carrying a lipid modification that extends how long the molecule persists in a model system, through binding to albumin. Attaching a fatty acid chain is a strategy used across many peptides, and in research it serves mainly to control pharmacokinetics. The literature describes cagrilintide as an agonist of amylin and calcitonin receptors, meaning it acts on AMY complexes rather than on the calcitonin receptor alone.

Cagrilintide has been studied in clinical trials. That is a fact from the published literature, not a promise of any outcome. Clinical studies reported changes in body weight and metabolic parameters, and the results varied with dosing schedule and study population. In the laboratory, cagrilintide is a reagent for receptor models and comparative studies.

Eloralintide: a selective amylin receptor agonist

Eloralintide is a selective amylin receptor agonist that has also been studied clinically. The word selective matters here. The molecule concentrates on one target, so an effect observed in a model can be linked to a specific signalling pathway rather than to the sum of several receptors. For teams that want to isolate amylin activity, that is a useful tool. Eloralintide is supplied as a lyophilized powder in 5 mg and 10 mg variants.

Why amylin is paired with GLP-1 agonists

GLP-1 receptors and amylin receptors operate in partly overlapping regions: the stomach, pancreas, brainstem and hypothalamus. In models, both pathways influence gastric emptying, glucagon release and satiety signalling. Because they activate different receptors, combining them lets researchers examine two signalling axes in parallel and ask whether the effect is additive or synergistic.

CagriSema in clinical research

The combination of cagrilintide and semaglutide, known in the literature as CagriSema, has been studied clinically. Semaglutide is a GLP-1 receptor agonist with a fatty acid chain that binds albumin, and it is a registered medicine in many countries. In the shop it is sold as a research reagent. The single-vial blend, listed as cagrilintide-semaglutide, lets you work with this same pairing of mechanisms in your own models.

Comparison: cagrilintide, the blend and eloralintide

Feature	Cagrilintide	Cagrilintide + semaglutide	Eloralintide
Class	amylin analogue	blend of an amylin analogue and a GLP-1 agonist	selective amylin receptor agonist
Main receptor target	AMY (CTR with RAMP)	AMY and the GLP-1 receptor	amylin receptor
Research status	studied clinically	studied clinically as CagriSema	studied clinically
Format in the shop	lyophilized, 2, 5, 10 and 20 mg	lyophilized, 2.5 + 2.5 mg, 5 + 5 mg, 10 + 10 mg	lyophilized, 5 and 10 mg
Typical use	receptor models, comparative studies	models of combined signalling	selectivity and amylin signalling assays

The table shows that the right molecule depends on the research question. If the goal is a single receptor, eloralintide is the cleaner choice. If you are interested in how amylin and GLP-1 signalling interact, the blend is the relevant option.

Working in the lab

A few habits pay off from the first day:

• Before preparing a solution, check the peptide content and molecular mass.
• Store lyophilized material according to the product page, away from light and moisture.
• Use the concentration calculator, which accounts for the mass of your batch.
• Keep separate vials for each compound and label them with the batch number.

A well-kept batch log saves time when results from two production runs need to be compared.

Why buy from MOLEVIA

MOLEVIA supplies research peptides and compounds as reagents for scientific research. Every batch is checked for the following:

• Purity of at least 99%, confirmed by HPLC.
• Molecular mass confirmed by MS.
• Same-day dispatch for orders placed by 14:00 on business days.
• InPost parcel locker delivery in Poland on the next business day, and DPD across Europe in 2-4 business days.
• Free shipping from 75 EUR, 65 GBP, 80 USD.
• Automatic volume discounts: 5% for 2 pieces, 10% for 3 pieces, 15% for 5 pieces.
• Bacteriostatic water, 10 ml, free with orders over 50 EUR (40 GBP, 55 USD) that include a peptide vial.
• Pay online by card, Apple Pay, Google Pay or BLIK (PLN only).

Order your research materials directly: cagrilintide, cagrilintide + semaglutide and eloralintide. You can browse the full range of incretin analogues in the incretin analogues category, and read about our quality standards on the quality page.

Key takeaways

• Amylin is released together with insulin and acts through AMY1, AMY2 and AMY3 receptors, which are calcitonin receptor complexes with RAMP1, RAMP2 or RAMP3.
• Cagrilintide is a long-acting amylin analogue that has been studied clinically.
• Eloralintide is a selective amylin receptor agonist that has also been studied clinically.
• Pairing amylin with a GLP-1 agonist, as in the CagriSema blend, lets you examine two signalling axes at once.
• Every product has purity of at least 99% (HPLC) and confirmed mass (MS).